SG11201607267SA - Human plasma kallikrein inhibitors - Google Patents
Human plasma kallikrein inhibitorsInfo
- Publication number
- SG11201607267SA SG11201607267SA SG11201607267SA SG11201607267SA SG11201607267SA SG 11201607267S A SG11201607267S A SG 11201607267SA SG 11201607267S A SG11201607267S A SG 11201607267SA SG 11201607267S A SG11201607267S A SG 11201607267SA SG 11201607267S A SG11201607267S A SG 11201607267SA
- Authority
- SG
- Singapore
- Prior art keywords
- human plasma
- plasma kallikrein
- kallikrein inhibitors
- inhibitors
- human
- Prior art date
Links
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 title 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949808P | 2014-03-07 | 2014-03-07 | |
| US201461981515P | 2014-04-18 | 2014-04-18 | |
| PCT/US2015/019535 WO2015134998A1 (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607267SA true SG11201607267SA (en) | 2016-09-29 |
Family
ID=54055948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607267SA SG11201607267SA (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
| SG10202001795XA SG10202001795XA (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202001795XA SG10202001795XA (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Country Status (33)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105228996B (zh) | 2013-03-25 | 2017-11-28 | ē¾ę¶ē¾ę½č“µå®å ¬åø | ä½äøŗå åXIaęå¶åēå«å代åē±»ēåę°¢å¼å¹å |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | č±åå”ē¾ē¶ęÆå”č£½č„ęéå ¬åø | éē°č”ēē© |
| NZ761182A (en) | 2014-01-31 | 2023-04-28 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2ā groups as factor xia inhibitors |
| NO2760821T3 (cg-RX-API-DMAC7.html) | 2014-01-31 | 2018-03-10 | ||
| NZ724250A (en) | 2014-03-07 | 2022-02-25 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| US10081623B2 (en) | 2014-09-04 | 2018-09-25 | Bristol-Myers Squibb Company | Diamide macrocycles that are FXIa inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| ES2905401T3 (es) * | 2015-10-01 | 2022-04-08 | Biocryst Pharm Inc | Inhibidores de calicreĆna plasmĆ”tica humana |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | ć¢ććŖćŖć³ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗļ¼ć¤ć³ć³ć¼ćć¬ć¼ććć | č£ä½ļ½å åć®å»å¦ēé害ć®ę²»ēć®ććć®å»č¬ååē© |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| UY38438A (es) * | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreĆna plasmĆ”tica |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| JP7668227B2 (ja) * | 2019-04-08 | 2025-04-24 | ćć¤ćŖćÆć©ć¤ć¹ć ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | č”ę¼æć«ćŖćÆć¬ć¤ć³é»å®³å¤ććć³ē¼é害ć«ććććć®ä½æēØę¹ę³ |
| WO2021025969A1 (en) | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| PE20221009A1 (es) | 2019-08-06 | 2022-06-15 | Biocryst Pharm Inc | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | å”å°ē»“ęÆå”å¶čÆęéå ¬åø | č”ęµęæč½éę¾é ¶ęå¶å |
| CN114258392A (zh) * | 2019-08-21 | 2022-03-29 | å”å°ē»“ęÆå”å¶čÆęéå ¬åø | é ¶ęå¶å |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | å¾·åē¾éä½³ę®·ę ¼ēæ°åéč”份ęéå ¬åø | ä½ēŗč”ę¼æęæč½éę¾é ¶ęå¶åä¹éč³ęē²éÆčŗč”ēē© |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| EP4116299A4 (en) | 2020-03-04 | 2024-03-27 | Medshine Discovery Inc. | HETEROCYCLIC COMPOUND |
| BR112022025528A2 (pt) | 2020-06-16 | 2023-01-17 | Merck Sharp & Dohme Llc | Composto, composiĆ§Ć£o farmacĆŖutica, e, mĆ©todos para tratar atividade visual prejudicada, retinopatia diabĆ©tica, edema macular diabĆ©tico, oclusĆ£o de veia retinal, angioedema hereditĆ”rio, diabete, pancreatite, hemorragia cerebral, nefropatia, cardiomiopatia, neuropatia, doenƧa intestinal inflamatĆ³ria, artrite, inflamaĆ§Ć£o, choque sĆ©ptico, hipotensĆ£o, cĆ¢ncer, sĆndrome da angĆŗstia respiratĆ³ria do adulto, coagulaĆ§Ć£o intravascular disseminada, coagulaĆ§Ć£o sanguĆnea durante cirurgia de desvio cardiopulmonar ou hemorragia do pĆ³s-operatĆ³rio de cirurgia e para tratar uveĆte, uveĆte posterior, edema macular relacionado com a idade Ćŗmido |
| MX2023000507A (es) * | 2020-07-10 | 2023-02-09 | Merck Sharp & Dohme Llc | Inhibidores de la calicreina plasmatica. |
| WO2022060842A1 (en) * | 2020-09-15 | 2022-03-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for predicting graft dysfunction with exosome proteins |
| EP4288430A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | čå·åå¹³ē§ęåå±ęéå ¬åø | č“ē½åøä»äøé“ä½ēå¶å¤ę¹ę³ |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| DE3633840A1 (de) | 1986-10-04 | 1988-04-14 | Hoechst Ag | Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| CZ225699A3 (cs) * | 1996-12-23 | 2000-09-13 | Du Pont Pharmaceuticals Company | DusĆkatĆ© heteroaromatickĆ© slouÄeniny jako inhibitory faktoru Xa |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| EE9900584A (et) * | 1997-06-19 | 2000-08-15 | Dupont Pharmaceuticals Company | Neutraalse P1 spetsiifilisusrĆ¼hmaga faktori Xa inhibiitorid |
| ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| WO1999032454A1 (en) * | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| ATE286026T1 (de) * | 1999-02-10 | 2005-01-15 | Mitsubishi Pharma Corp | Amid-derivate und deren medizinische verwendung |
| WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| WO2002000651A2 (en) * | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP5046465B2 (ja) | 2000-06-27 | 2012-10-10 | ć©ćć©ććŖćŖć¹ć»ćµć«ććć»ć½ć·ćØćććć»ć¢ććć | ć¢ćŖć¼ć«ć¢ć«ćć«ć¢ćć³ććčŖå°ćććć«ć«ćć”ć¼ć |
| EE200300116A (et) | 2000-09-22 | 2005-04-15 | Bristol-Myers Squibb Pharma Company | Efektiivne meetod faktori Xa inhibiitori valmistamiseks |
| CN1264825C (zh) | 2001-04-12 | 2006-07-19 | å¼Ā·å夫ę¼-ęē½åęéå ¬åø | ēØä½mGluR2ę®ęåā ”ēäŗę°¢ļ¼čÆ并[b][1,4]äŗę°®ęä¬ļ¼2ļ¼é ®č”ēē© |
| TWI325302B (en) * | 2001-08-13 | 2010-06-01 | Du Pont | Benzoxazinone compounds |
| JP4448327B2 (ja) * | 2001-08-13 | 2010-04-07 | ć¤ć¼ć»ć¢ć¤ć»ćć„ćć³ć»ćć¦ć»ćć ć¼ć«ć»ć¢ć³ćć»ć«ć³ććć¼ | ę°č¦ē½®ęļ¼ļ½āćøććććć©ć¾ć¼ć«ććććć®č£½é ććć³ä½æēØ |
| US20040235959A1 (en) * | 2001-09-21 | 2004-11-25 | Lahm George Philip | Insecticidal diamides |
| TW200724033A (en) | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| TW200303309A (en) | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| BR0311707A (pt) * | 2002-06-13 | 2005-03-15 | Du Pont | Composto, composiĆ§Ć£o e mĆ©todo de controle de pelo menos uma praga invertebrada |
| DE10229070A1 (de) * | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| EP1590329A1 (fr) | 2003-01-28 | 2005-11-02 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | ć¤ćć³čŖå°ä½åć³ć¢ććčŖå°ä½ |
| JP2007532661A (ja) | 2004-04-13 | 2007-11-15 | ć¤ć¼ć»ć¢ć¤ć»ćć„ćć³ć»ćć¦ć»ćć ć¼ć«ć»ć¢ć³ćć»ć«ć³ććć¼ | ć¢ć³ćć©ćć«ć¢ććę®ŗč«å¤ |
| US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
| US20060069270A1 (en) | 2004-09-27 | 2006-03-30 | Rafael Shapiro | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| AU2005306363B2 (en) | 2004-11-18 | 2012-08-09 | E. I. Du Pont De Nemours And Company | Anthranilamide insecticides |
| RU2394021C2 (ru) * | 2004-12-07 | 2010-07-10 | Š¢Š¾ŃŠ¼Š° ŠŠµŠ¼ŠøŠŗŠ°Š» ŠŠ¾., ŠŃŠ“. | ŠŠ¾Š²Š¾Šµ ŠæŃŠ¾ŠøŠ·Š²Š¾Š“Š½Š¾Šµ Š°Š½ŃŃŠ°Š½ŠøŠ»Š¾Š²Š¾Š¹ ŠŗŠøŃŠ»Š¾ŃŃ ŠøŠ»Šø ŠµŠ³Š¾ ŃŠ¾Š»Ń |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| GB0516703D0 (en) | 2005-08-15 | 2005-09-21 | Syngenta Participations Ag | Novel insecticides |
| EP1937664B1 (en) | 2005-10-14 | 2011-06-15 | Sumitomo Chemical Company, Limited | Hydrazide compound and pesticidal use of the same |
| JP5186751B2 (ja) * | 2005-10-14 | 2013-04-24 | ä½ååå¦ę Ŗå¼ä¼ē¤¾ | ććć©ćøćååē©ććć³ćć®ę害ēē©é²é¤ēØé |
| PE20070795A1 (es) | 2005-10-28 | 2007-08-24 | Lilly Co Eli | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa |
| EP1988777B1 (en) | 2006-02-09 | 2011-09-21 | Athersys, Inc. | Pyrazoles for the treatment of obesity and other cns disorders |
| NZ573573A (en) * | 2006-05-16 | 2011-10-28 | Boehringer Ingelheim Int | Substituted prolinamides, production thereof and their use as drugs |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | č¾å ęå¼čµē¹å¶čÆč”份ęéå ¬åø | č”ęµęæč½éę¾é ¶ęå¶å |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| JP2010509349A (ja) | 2006-11-03 | 2010-03-25 | ć¢ć¤ć¢ć¼ć«ćØć ć»ćŖććććć»ć©ć¤ć¢ććŖćć£ć»ć«ć³ććć¼ | ćæć³ććÆč³Ŗććć¼ć¼é»å®³å¤ćØćć¦ć®ååē©ććć³ēµęē© |
| EP2121621B1 (en) * | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| CN101298451B (zh) | 2007-04-30 | 2013-01-30 | äøå½äøåč”份ęéå ¬åø | čÆē²é °čŗē±»ååē©åå ¶åŗēØ |
| WO2008134969A1 (fr) | 2007-04-30 | 2008-11-13 | Sinochem Corporation | ComposƩs benzamides et leurs applications |
| ES2535276T3 (es) * | 2008-12-18 | 2015-05-07 | Bayer Cropscience Ag | Amidas del Ć”cido antranĆlico sustituidas con tetrazol como plaguicidas |
| WO2010108733A1 (en) | 2009-03-26 | 2010-09-30 | Syngenta Participations Ag | Insecticidal compounds |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| JP2013515000A (ja) | 2009-12-18 | 2013-05-02 | ć¢ćÆćć£ććµć¤ć ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗ ć¤ć³ć³ć¼ćć¬ć¤ćć£ćć | č”ę¼æć«ćŖćÆć¬ć¤ć³ć®é»å®³č¬ć®ćććć©ćć° |
| NZ601085A (en) | 2010-02-01 | 2015-04-24 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JPWO2011118818A1 (ja) | 2010-03-26 | 2013-07-04 | å³ć®ē“ ę Ŗå¼ä¼ē¤¾ | ć¢ććøćć¢ććŖć³čŖå°ä½ |
| CN102285963B (zh) | 2010-06-21 | 2014-04-09 | äøå½äøåč”份ęéå ¬åø | 3-ē²ę°§åŗå”åé °čŗē±»ååē©åå ¶åŗēØ |
| AR082498A1 (es) | 2010-08-20 | 2012-12-12 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide |
| MX2013005008A (es) | 2010-11-10 | 2013-08-01 | Gruenenthal Gmbh | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide. |
| EP2702055A1 (en) | 2011-04-11 | 2014-03-05 | Nerviano Medical Sciences S.r.l. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| US8691861B2 (en) * | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2013036232A2 (en) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| CN104066720A (zh) | 2011-11-09 | 2014-09-24 | ę ¼å伦å”å°ęéå ¬åø | ä½äøŗē±»é¦čē“ åä½é ä½ēå ·ęč¢«å«so2-åŗå¢å代ēčÆåŗåŗå¢ēč¢«å代ēåŗäŗå”ååŗēē¾§é °čŗåč²č”ēē© |
| CN103467380B (zh) | 2013-09-29 | 2015-06-24 | åå¼å¤§å¦ | äøē±»å代čÆåŗå”åé °čŗč”ēē©åå ¶å¶å¤ę¹ę³ååŗēØ |
| NZ724250A (en) | 2014-03-07 | 2022-02-25 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreĆna plasmĆ”tica |
| PE20221009A1 (es) | 2019-08-06 | 2022-06-15 | Biocryst Pharm Inc | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso |
-
2015
- 2015-03-09 NZ NZ724250A patent/NZ724250A/en unknown
- 2015-03-09 PT PT201917473T patent/PT3828173T/pt unknown
- 2015-03-09 CN CN202110045874.9A patent/CN113307772B/zh active Active
- 2015-03-09 RS RS20221083A patent/RS63763B1/sr unknown
- 2015-03-09 JP JP2016555752A patent/JP6574435B2/ja active Active
- 2015-03-09 PL PL20191747.3T patent/PL3828173T3/pl unknown
- 2015-03-09 US US15/123,059 patent/US10125102B2/en active Active
- 2015-03-09 SM SM20210031T patent/SMT202100031T1/it unknown
- 2015-03-09 EP EP15759254.4A patent/EP3113772B8/en active Active
- 2015-03-09 HU HUE15759254A patent/HUE052668T2/hu unknown
- 2015-03-09 EP EP20191747.3A patent/EP3828173B1/en active Active
- 2015-03-09 ES ES20191747T patent/ES2932406T3/es active Active
- 2015-03-09 RS RS20201483A patent/RS61159B1/sr unknown
- 2015-03-09 HR HRP20221373TT patent/HRP20221373T1/hr unknown
- 2015-03-09 MX MX2016011468A patent/MX377845B/es unknown
- 2015-03-09 LT LTEP20191747.3T patent/LT3828173T/lt unknown
- 2015-03-09 KR KR1020237008388A patent/KR102736869B1/ko active Active
- 2015-03-09 EP EP25184854.5A patent/EP4663636A2/en active Pending
- 2015-03-09 SI SI201531442T patent/SI3113772T1/sl unknown
- 2015-03-09 HU HUE20191747A patent/HUE060660T2/hu unknown
- 2015-03-09 EP EP22191079.7A patent/EP4180424B1/en active Active
- 2015-03-09 LT LTEP15759254.4T patent/LT3113772T/lt unknown
- 2015-03-09 MA MA53399A patent/MA53399B1/fr unknown
- 2015-03-09 MY MYPI2016001634A patent/MY199131A/en unknown
- 2015-03-09 DK DK20191747.3T patent/DK3828173T3/da active
- 2015-03-09 ES ES15759254T patent/ES2836373T3/es active Active
- 2015-03-09 ES ES22191079T patent/ES3039514T3/es active Active
- 2015-03-09 SG SG11201607267SA patent/SG11201607267SA/en unknown
- 2015-03-09 DK DK15759254.4T patent/DK3113772T3/da active
- 2015-03-09 PT PT157592544T patent/PT3113772T/pt unknown
- 2015-03-09 IL IL280785A patent/IL280785B2/en unknown
- 2015-03-09 AU AU2015226855A patent/AU2015226855C1/en active Active
- 2015-03-09 CA CA3164693A patent/CA3164693A1/en active Pending
- 2015-03-09 CA CA2941380A patent/CA2941380C/en active Active
- 2015-03-09 PH PH1/2016/501750A patent/PH12016501750B1/en unknown
- 2015-03-09 BR BR112016020199A patent/BR112016020199A8/pt not_active Application Discontinuation
- 2015-03-09 CN CN201580022369.5A patent/CN106257976B/zh active Active
- 2015-03-09 MX MX2020013059A patent/MX2020013059A/es unknown
- 2015-03-09 WO PCT/US2015/019535 patent/WO2015134998A1/en not_active Ceased
- 2015-03-09 NZ NZ762034A patent/NZ762034A/en unknown
- 2015-03-09 PL PL15759254T patent/PL3113772T3/pl unknown
- 2015-03-09 SG SG10202001795XA patent/SG10202001795XA/en unknown
- 2015-03-09 HR HRP20201916TT patent/HRP20201916T1/hr unknown
- 2015-03-09 KR KR1020167026786A patent/KR102510427B1/ko active Active
- 2015-03-09 EA EA201691803A patent/EA036251B1/ru unknown
- 2015-03-09 SM SM20230002T patent/SMT202300002T1/it unknown
-
2016
- 2016-08-28 IL IL247518A patent/IL247518B/en active IP Right Grant
- 2016-09-13 ZA ZA2016/06320A patent/ZA201606320B/en unknown
-
2018
- 2018-05-11 US US15/977,129 patent/US10329260B2/en active Active
- 2018-06-15 US US16/009,943 patent/US10633345B2/en active Active
-
2019
- 2019-05-01 US US16/400,798 patent/US10689346B2/en active Active
- 2019-08-16 JP JP2019149385A patent/JP6915003B2/ja active Active
-
2020
- 2020-03-24 US US16/828,763 patent/US11203574B2/en active Active
- 2020-03-24 US US16/828,755 patent/US11192861B2/en active Active
- 2020-04-10 US US16/845,833 patent/US11230530B2/en active Active
- 2020-10-27 AU AU2020260400A patent/AU2020260400B2/en active Active
- 2020-12-08 CY CY20201101164T patent/CY1123810T1/el unknown
-
2021
- 2021-07-14 JP JP2021116716A patent/JP2021169499A/ja active Pending
- 2021-10-08 CY CY2021029C patent/CY2021029I2/el unknown
- 2021-10-14 LU LU00233C patent/LUC00233I2/fr unknown
- 2021-10-25 FR FR21C1048C patent/FR21C1048I2/fr active Active
- 2021-10-25 HU HUS2100045C patent/HUS2100045I1/hu unknown
- 2021-10-26 LT LTPA2021524C patent/LTC3113772I2/lt unknown
- 2021-11-01 NL NL301142C patent/NL301142I2/nl unknown
- 2021-11-09 US US17/522,065 patent/US11685721B2/en active Active
- 2021-11-15 US US17/526,377 patent/US11708332B2/en active Active
- 2021-12-07 US US17/543,929 patent/US11708333B2/en active Active
-
2022
- 2022-10-25 AU AU2022259742A patent/AU2022259742B2/en active Active
- 2022-11-07 NO NO2022046C patent/NO2022046I1/no unknown
-
2023
- 2023-04-18 US US18/136,016 patent/US12162838B2/en active Active
- 2023-04-18 US US18/136,025 patent/US12116346B2/en active Active
- 2023-11-06 JP JP2023189564A patent/JP2023181543A/ja active Pending
-
2024
- 2024-09-24 US US18/894,797 patent/US20250257040A1/en active Pending
- 2024-10-11 US US18/913,643 patent/US20250270171A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280785A (en) | Human plasma kallikrein inhibitors | |
| IL287113A (en) | smyd inhibitors | |
| PL3207043T6 (pl) | Inhibitory dihydropirolopirydynowe ror-gamma | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| IL291268A (en) | Human plasma kallikrein inhibitors | |
| PT3097084T (pt) | Novos inibidores de calicreĆna 7 | |
| GB201401005D0 (en) | Inhibitor | |
| GB201418154D0 (en) | Inhibitors |